BG106548A - Synergistic combinations of an nk1 receptor antagonist and a gaba structural analog - Google Patents

Synergistic combinations of an nk1 receptor antagonist and a gaba structural analog

Info

Publication number
BG106548A
BG106548A BG106548A BG10654802A BG106548A BG 106548 A BG106548 A BG 106548A BG 106548 A BG106548 A BG 106548A BG 10654802 A BG10654802 A BG 10654802A BG 106548 A BG106548 A BG 106548A
Authority
BG
Bulgaria
Prior art keywords
receptor antagonist
synergistic combinations
structural analog
gaba
gaba analog
Prior art date
Application number
BG106548A
Other languages
Bulgarian (bg)
English (en)
Inventor
John Hughes
Lakhbir Singh
Original Assignee
Warner-Lambert Company Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warner-Lambert Company Llc filed Critical Warner-Lambert Company Llc
Publication of BG106548A publication Critical patent/BG106548A/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Virology (AREA)
  • Pain & Pain Management (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
BG106548A 1999-10-07 2002-03-22 Synergistic combinations of an nk1 receptor antagonist and a gaba structural analog BG106548A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US15827199P 1999-10-07 1999-10-07
PCT/EP2000/009858 WO2001024792A1 (en) 1999-10-07 2000-10-05 Synergistic combinations of an nk1 receptor antagonist and a gaba structural analog

Publications (1)

Publication Number Publication Date
BG106548A true BG106548A (en) 2002-12-29

Family

ID=22567369

Family Applications (1)

Application Number Title Priority Date Filing Date
BG106548A BG106548A (en) 1999-10-07 2002-03-22 Synergistic combinations of an nk1 receptor antagonist and a gaba structural analog

Country Status (38)

Country Link
EP (2) EP1221950B1 (cs)
JP (2) JP2003510356A (cs)
KR (1) KR20020060192A (cs)
CN (1) CN1387434A (cs)
AP (1) AP2002002501A0 (cs)
AR (1) AR029646A1 (cs)
AT (1) ATE269072T1 (cs)
AU (2) AU7663300A (cs)
BG (1) BG106548A (cs)
BR (1) BR0014598A (cs)
CA (1) CA2385930A1 (cs)
CO (1) CO5280195A1 (cs)
CR (1) CR6614A (cs)
CZ (1) CZ20021116A3 (cs)
DE (1) DE60011650T2 (cs)
DK (1) DK1221950T3 (cs)
EA (1) EA004266B1 (cs)
EE (1) EE200200185A (cs)
ES (1) ES2220542T3 (cs)
GT (1) GT200000166A (cs)
HR (1) HRP20020286A2 (cs)
HU (1) HUP0203466A3 (cs)
IL (1) IL148965A0 (cs)
IS (1) IS6318A (cs)
MA (1) MA26826A1 (cs)
MX (1) MXPA02003484A (cs)
NO (1) NO20021625L (cs)
NZ (1) NZ517949A (cs)
OA (1) OA12063A (cs)
PA (1) PA8504301A1 (cs)
PE (1) PE20010708A1 (cs)
PL (1) PL357498A1 (cs)
PT (1) PT1221950E (cs)
SK (1) SK4542002A3 (cs)
TR (1) TR200200913T2 (cs)
UY (1) UY26376A1 (cs)
WO (2) WO2001024792A1 (cs)
ZA (1) ZA200202675B (cs)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU228426B1 (hu) 1996-07-24 2013-03-28 Warner Lambert Co Izobutil-gaba és származékai alkalmazása fájdalom kezelésére alkalmas gyógyszer elõállítására
US8048917B2 (en) 2005-04-06 2011-11-01 Xenoport, Inc. Prodrugs of GABA analogs, compositions and uses thereof
JP2005523334A (ja) * 2002-04-24 2005-08-04 サイプレス バイオサイエンス， インコーポレイテッド ストレス関連障害を含む機能的身体障害の予防および処置
WO2004032905A1 (en) * 2002-10-08 2004-04-22 Ranbaxy Laboratories Limited Gabapentin tablets and methods for their preparation
WO2004084881A1 (en) * 2003-03-21 2004-10-07 Dynogen Pharmaceuticals, Inc. METHODS FOR TREATING FUNCTIONAL BOWEL DISORDERS USING α2δ SUBUNIT CALCIUM CHANNEL MODULATORS WITH SMOOTH MUSCLE MODULATORS
EP1492519B1 (en) * 2003-03-21 2006-11-15 Dynogen Pharmaceuticals, Inc. Methods for treating lower urinary tract disorders using antimuscarinics and alpha-2-delta subunit calcium channel modulators
US20060264509A1 (en) * 2003-03-21 2006-11-23 Fraser Matthew O Methods for treating pain using smooth muscle modulators and a2 subunit calcium channel modulators
EP1543831A1 (en) * 2003-12-18 2005-06-22 Pfizer GmbH Arzneimittelwerk Gödecke Pregabalin composition
DE102007019071A1 (de) * 2007-04-23 2008-10-30 Ratiopharm Gmbh Stabilisierte pharmazeutische Zusammensetzung enthaltend Pregabalin
RU2544552C2 (ru) 2010-07-30 2015-03-20 Торэй Индастриз, Инк. Терапевтическое средство или профилактическое средство для нейропатической боли
CN107050456B (zh) * 2010-09-28 2022-08-12 加利福尼亚大学董事会 治疗代谢综合征相关疾病的gaba激动剂和治疗或预防i型糖尿病的gaba组合
AU2020249679B2 (en) 2019-03-26 2024-11-21 Orion Corporation Pregabalin formulations and use thereof
WO2022234110A1 (en) * 2021-05-07 2022-11-10 Plus Vitech, S.L. Gamma-aminobutyric acid derivatives for use in cancer therapy

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5025035A (en) * 1990-10-12 1991-06-18 Warner-Lambert Company Method of treating depression
US5792796A (en) * 1994-07-27 1998-08-11 Warner-Lambert Company Methods for treating anxiety and panic
US5510381A (en) * 1995-05-15 1996-04-23 Warner-Lambert Company Method of treatment of mania and bipolar disorder
CA2266773A1 (en) * 1996-10-07 1998-04-16 Merck Sharp & Dohme Limited Use of a nk-1 receptor antagonist and an antidepressant and/or an anti-anxiety agent
JP2001504848A (ja) * 1996-12-02 2001-04-10 メルク シヤープ エンド ドーム リミテツド 重症不安障害の治療のためのｎｋ−１受容体拮抗薬の使用

Also Published As

Publication number Publication date
HRP20020286A2 (en) 2003-08-31
MXPA02003484A (es) 2004-09-10
ZA200202675B (en) 2003-04-15
HUP0203466A2 (hu) 2003-02-28
EA200200303A1 (ru) 2002-08-29
AP2002002501A0 (en) 2002-06-30
DK1221950T3 (da) 2004-09-20
HUP0203466A3 (en) 2005-03-29
PA8504301A1 (es) 2002-08-26
WO2001024792A9 (en) 2002-09-06
CO5280195A1 (es) 2003-05-30
KR20020060192A (ko) 2002-07-16
EE200200185A (et) 2003-04-15
PL357498A1 (en) 2004-07-26
CN1387434A (zh) 2002-12-25
NO20021625D0 (no) 2002-04-05
DE60011650D1 (de) 2004-07-22
AU1696201A (en) 2001-05-10
EA004266B1 (ru) 2004-02-26
AU7663300A (en) 2001-05-10
CA2385930A1 (en) 2001-04-12
IL148965A0 (en) 2002-11-10
MA26826A1 (fr) 2004-12-20
PE20010708A1 (es) 2001-07-27
EP1221950B1 (en) 2004-06-16
PT1221950E (pt) 2004-08-31
TR200200913T2 (tr) 2002-09-23
WO2001024791A1 (en) 2001-04-12
DE60011650T2 (de) 2005-07-14
GT200000166A (es) 2002-03-30
NO20021625L (no) 2002-04-05
JP2003510356A (ja) 2003-03-18
CZ20021116A3 (cs) 2003-05-14
SK4542002A3 (en) 2003-09-11
ATE269072T1 (de) 2004-07-15
JP2003510355A (ja) 2003-03-18
ES2220542T3 (es) 2004-12-16
IS6318A (is) 2002-03-21
NZ517949A (en) 2003-08-29
CR6614A (es) 2003-12-04
EP1233766A1 (en) 2002-08-28
WO2001024792A1 (en) 2001-04-12
AR029646A1 (es) 2003-07-10
BR0014598A (pt) 2002-06-11
EP1221950A1 (en) 2002-07-17
OA12063A (en) 2006-05-03
UY26376A1 (es) 2000-12-29

Similar Documents

Publication Publication Date Title
WO2001078698A3 (en) Use of ngf-antagonists for the prevention or treatment of chronic visceral pain
MY127980A (en) A pyrrolidineacetamide derivative alone or in combination for treatment of cns disorders
HUP0202319A3 (en) Use of mek inhibitors for the preparation of pharmaceutical compositions treating chronic pain
BG104727A (en) Pharmaceutical composition of topiramate
AU2003301190A1 (en) Administration of capsaicinoids
HK1040945A1 (zh) 包含曲马多物质和选择性cox-2抑制剂药物的组合物
ZA200110504B (en) Dietary or pharmaceutical compositions for use for the prevention or treatment of hyperoxaluria.
BG106548A (en) Synergistic combinations of an nk1 receptor antagonist and a gaba structural analog
MXPA06000705A (es) Combinacion de antagonista del receptor 2 de glutamato metabotropico (mglur2) e inhibidor de acetilcolinesterasa (ache) para tratar trastornos neurologicos agudos y/o cronicos.
IL101358A0 (en) Crystalline tiagabine hydrochloride monohydrate,its preparation and pharmaceutical compositions containing it
EP1032556A4 (en) PHARMACEUTICALLY EFFECTIVE COMPOUNDS AND METHODS OF THEIR APPLICATION
GB2274777B (en) Synergistic combination of compounds having an antagonist effect on nk1 and on nk2 receptors
EP0657167A3 (fr) Application de l'oenothéine B pour obtenir un médicament destiné au traitement des troubles liés à l'hyperandrogénie, les compositions pharmaceutiques le contenant et un procédé de préparation à partir d'Epilobium Parviflorum.
PL1656131T3 (pl) Zastosowanie betainy w leczeniu chromania przestankowego
BG105962A (en) Use of saredutant and the pharmaceutically acceptable salts thereof to produce medicaments used to treat or prevent mood disorders, adjustment disorders or mixed anxiety-depression disorders
IL145645A0 (en) N-(2-phenyl-4-amino-butyl)-1-naphthamides as neurokinin-1 receptor antagonists
MX9708394A (es) Composicion farmaceutica que contiene clorhidrato de tiagabina y el proceso para su preparacion.
CA2433785A1 (en) Pharmaceutical compositions which inhibit vascular proliferation and method of use thereof
EE200100689A (et) IL6RIL6 kimääri kasutamine ravimi valmistamiseks,mis on ette nähtud neuroloogiliste haiguste ravimiseks, ning farmatseutiline kompositsioon
MY128529A (en) Use of cilobradine or the pharmaceutically acceptable salts thereof for the treatment or prevention of heart failure
EP0743068A3 (en) Composition for inhibiting bone loss containing vanadyl sulfate
CY2499B1 (en) Use of nk-1 receptor antagonists for treating stress disorders.
HUP9903375A2 (hu) Olanzapint és fájdalomcsillapító hatóanyagot tartalmazó szinergista hatású gyógyszerkészítmények
HUP0203309A3 (en) Therapeutic combinations of (s)-2-(benzylamino-methyl)-2,3,8,9,-tetrahydro-7h-1,4-dioxino(2,3)-e indol-8-one and neuroleptics for treatment or prevention of phychotic disorders and pharmaceutical compositions containing them
IL156144A0 (en) Novel therapeutic use of a thienylcyclohexylamine derivative